.webp)
Related Content
Download content relating to this event and topic.
Oligos & Peptides World Asia 2027
2nd Edition
Advancing Oligonucleotide & Peptide Therapeutics from Clinical R&D to Manufacturing in Asia
Join the Oligos & Peptides World Asia 2027, where industry leaders from biopharma and big pharma converge to foster collaboration, breakthrough therapies, and scalable manufacturing in Asia’s rapidly growing oligonucleotide, RNA and peptide sector.
Sands Expo & Convention Centre
23
March
-
24
March
2027
00
Days
00
Hours
00
Mins
00
Secs
300
+
Attendees
Maximum Attendees
120
+
Companies
35
+
Speakers
10
+
Case Studies
+
Interactive Sessions
20
+
Networking Hours
About the Event
The Oligos & Peptides World Asia 2027 is the APAC region’s leading platform dedicated to advancing oligonucleotide and peptide-based therapeutics. Covering the entire value chain, from early-stage R&D and clinical trials through to large-scale manufacturing, #OPWA2027 brings together the key stakeholders leaders from biopharma and big pharma, alongside regulatory experts, research institutes, tech innovators shaping the development and commercialisation of these next-generation therapies. The event aims to accelerate development pipelines and drive manufacturing excellence in oligonucleotide and peptide therapies.
Spanning eight focused sessions and case studies from across APAC, the Oligos & Peptides World Asia 2027 will explore the latest advancements in ASOs, siRNA, and peptide therapeutics; innovative delivery and formulation technologies; and progress in clinical trials and translational research across the region. The programme will also address scalable manufacturing, evolving regulatory frameworks, emerging digital and platform innovations, and best practices in quality and analytical strategies — offering a comprehensive view of Asia’s expanding oligonucleotide and peptide ecosystem, from R&D to large-scale production.
.webp)
Co-Located Events
Visit the event page to view more content.
Awards Cerermony
Visit the awards page to view more content.
Agenda at a Glance
View the Key Themes for
Oligos & Peptides World Asia 2027
No items found.
Ready to attend?
Register today to secure your ticket.
Speakers
Esteemed Voices From the Industry
Our selected experts will share insights on the latest trends, challenges, and developments in this dynamic field. Engage in unique discussions, learn about cutting-edge scientific discoveries, and explore the future of biopharmaceuticals with these influential thought leaders.
.webp)
Rakesh Veedu
Murdoch University/ ProGenis Pharmaceuticals
Professor/Co-Founder & MD/CEO
Australia
Connect on LinkedInAdvisory Board Commitee
Chairman
Rakesh Veedu
Professor/Co-Founder & MD/CEO
Murdoch University/ ProGenis Pharmaceuticals
Australia
Advisory Board Commitee
Chairman
Dr. Bin Xia Yang
Director
Hengrui R&D Centre
Singapore
Advisory Board Commitee
Chairman
Dr. Pratik Dave
Senior Scientist
Roche
Switzerland
Advisory Board Commitee
Chairman
Dr. Bharti Prafulla Deshmukh
HOD of RND Peptide Genric
Hovid Bhd
Malaysia
.webp)
Wonil Kim
Aston Sciences
Executive Vice President & CSO
South Korea
Wonil Kim, Ph.D., is Chief Scientific Officer at Aston Sci, Inc., where he leads the development of mRNA-based vaccines for oncology and infectious diseases using the AI-driven Th-Vac® platform. He earned his Ph.D. in Molecular, Cellular, Developmental Biology and Genetics from the University of Minnesota and completed postdoctoral fellowships at Harvard Medical School and the NIH. Dr. Kim has served as a Staff Scientist at St. Jude Children's Research Hospital, where he pioneered cancer biology programs, and has held senior R&D positions at GeneOne Life Science and Cyrus Therapeutics. He is recognized for his expertise in mRNA vaccine design and cancer immunology.
Advisory Board Commitee
Chairman
Wonil Kim
Executive Vice President & CSO
Aston Sciences
South Korea
.webp)
Andy Xian Zeng
Byterna Therapeutics
CEO and Co-Founder
China
Dr. Xian Zeng, the Co-Founder and CEO of Byterna Therapeutics, leads this enterprising startup at the vanguard of groundbreaking circular mRNA-based immunotherapies.
Holding a PhD in pharmaceutical science from the National University of Singapore, he previously served as Associate Professor at Fudan University School of Pharmacy, spearheading interdisciplinary research in AI-empowered mRNA drug discovery.
Under his visionary leadership, Byterna is pioneering SEAA (Safe, Effective, Accessible, Affordable) in vivo CAR-T therapies for global patients, leveraging proprietary circular mRNA platforms and targeted delivery systems.
Advisory Board Commitee
Chairman
Andy Xian Zeng
CEO and Co-Founder
Byterna Therapeutics
China
Advisory Board Commitee
Chairman
Stephen Lin
CEO
Exo-One Bio
Taiwan
Alap Gandhi
GSK
Country Medical Director
Malaysia
Dr. Alap Gandhi, Country Medical Director, GSK Malaysia, brings with himself over 17 years of experience in the healthcare industry having worked with organizations like WHO, GSK and AstraZeneca pharmaceuticals.
Dr. Alap Strongly believes in the purpose to unite science, technology, and talent to get ahead of disease together and positively impact the health of billion people.
His interests include application of the science of medicines and vaccines from early development and throughout the lifecycle to deliver improvement in patient and population health outcomes. Dr. Alap is MBBS, MD and has additional qualifications of eMBA, PDCR and PGCDDR (Kings College, London).
Advisory Board Commitee
Chairman
Alap Gandhi
Country Medical Director
GSK
Malaysia
Want to Speak at This Event?
Join the roster of esteemed colleagues to discuss what you or your company are bringing to the biopharmaceutical industry.
Apply to SpeakPrincipal
No items found.
Platinum
No items found.
Gold
No items found.
Silver
No items found.
Bronze
No items found.
Exhibition & Showcase
Associate
No items found.
Media & Publicity
.png)
Registration
Select the relevant ticket for your organisation.
*Delegate tickets must be purchased under the correct classification.
Biopharma tickets are strictly reserved for professionals employed by pharmaceutical or biopharmaceutical companies that develop, own, or commercialise therapeutic drug products, including organisations with an internal drug pipeline spanning discovery, development, clinical, or commercial stages. This category applies to companies whose primary business is the development or manufacture of drug products, not the provision of enabling technologies, equipment, platforms, or services.
Service, Solution, and Technology Provider tickets apply to all organisations offering services, platforms, technologies, equipment, consultancy, manufacturing services, or commercial solutions to the pharma and biopharma industry. This includes, but is not limited to, CROs, CDMOs, technology and equipment vendors, consultants, suppliers, and solution providers, regardless of scientific or technical focus.
Important Notice
All registrations are reviewed to ensure correct classification. Purchasing an incorrect ticket does not guarantee entry to the event. IMAPAC retains full discretion to deny access, reclassify registrations, and issue an invoice for the price difference required for correct attendance. Incorrect ticket purchases made under an inappropriate classification are not eligible for refunds under any circumstances, including where the registrant chooses not to upgrade or attend.
BigPharma, BioPharmas, Academics (Asia)
SGD 2,095 (Final Call Rate)
Early Bird Rate : SGD 1,495
Use discount code: EARLYBIRD
(Valid until 3rd October 2026)
Registration Open Rate : SGD 1,695
Use discount code: REGISTRATIONOPEN
(Valid until 5th December 2026)
Standard Rate : SGD 1,895
Use discount code: STANDARD
(Valid until 6th February 2027)
Final Call Rate : SGD 2,095
Applicable to company profiles (headquartered within the APAC region):
- BioPharma
- Academic Institutions
- Research Organisations
Job Profiles: Manufacturing, Bioprocessing, Production, USP, DSP, Operations, Site Heads, Drug Substance and Product Manufacturing, Process Development, Quality, Analytics and other related technical designations
BigPharma, BioPharmas, Academics (outside Asia)
SGD 2,595 (Final Call Rate)
Early Bird Rate : SGD 1,995
Use discount code: EARLYBIRD
(Valid until 3rd October 2026)
Registration Open Rate : SGD 2,195
Use discount code: REGISTRATIONOPEN
(Valid until 5th December 2026)
Standard Rate : SGD 2,395
Use discount code: STANDARD
(Valid until 6th February 2027)
Final Call Rate : SGD 2,595
Applicable to company profiles (headquartered outside of the APAC region):
- BioPharma
- Academic Institutions
- Research Organisations
Job Profiles: Manufacturing, Bioprocessing, Production, USP, DSP, Operations, Site Heads, Drug Substance and Product Manufacturing, Process Development, Quality, Analytics and other related technical designations
Service & Solution Provider
SGD 3,595 (Final Call Rate)
Early Bird Rate : SGD 2,995
Use discount code: EARLYBIRD
(Valid until 3rd October 2026)
Registration Open Rate : SGD 3,195
Use discount code: REGISTRATIONOPEN
(Valid until 5th December 2026)
Standard Rate : SGD 3,395
Use discount code: STANDARD
(Valid until 6th February 2027)
Final Call Rate : SGD 3,595
Applicable to company profiles:
- Technology, Service, and Solution Providers
- CDMO/ CMO
Job Profiles: Business Development, Marketing, and Sales
Registration
Register Your Interest
Be the first in line!
Register your interest to get access to tickets as soon as they go live.
Want to Sponsor This Event?
Contact the IMAPAC to learn about our sponsorship process, rates and more.
Pre Conference Workshops & Other Sessions
Visit the event page to view more content.
No items found.
_result.webp)
Frequently Asked Questions
How can I stay updated on event details and announcements?
To stay informed about event updates, including date, venue, and agenda, please subscribe to our our official social media channels for real-time updates and announcements.
What can I expect to learn and explore during the event?
The conference will provide a comprehensive learning experience covering various aspects of the dynamic biopharmaceutical industry, ensuring attendees gain valuable insights and knowledge.
What safety measures will be in place to ensure the safety of attendees?
We are committed to ensuring the safety and well-being of all attendees. We will implement rigorous safety measures in line with local health guidelines and regulations. Specific safety measures will be communicated closer to the event date to ensure they align with the most up-to-date health recommendations. Rest assured, your safety is our priority.
Can I submit a presentation to be a speaker at this event?
We welcome presentation submissions. If you’re interested in speaking at the event, please visit this page on our website for submission guidelines and deadlines.
What type of professionals benefit most from attending?
Our event is designed to cater to a wide range of professionals within the biopharmaceutical industry, including researchers, scientists, executives, regulatory experts, and professionals involved in drug development and manufacturing.
What advantages does this conference offer participants?
Participants can expect to gain insights from industry experts, network with peers, and stay up-to-date with the latest trends and innovations in biopharmaceuticals
Are there networking opportunities or special events planned?
Yes, we have networking sessions, workshops, and social events scheduled throughout the event to facilitate connections and collaborations among attendees.
Are there sponsorship opportunities for this event?
Yes, we offer sponsorship and exhibition opportunities for businesses and organisations.
How can I register for the event?
To register for the event, you'll find multiple "register" buttons on this page to get started. You’ll find detailed instructions and options for registration, including pricing and deadlines.
Be a Part of This Event!
Don't miss out on unique networking, speaking and sponsorship opportunities.
